Effect of ischemic preconditioning under hepatic inflow occlusion on the SGPT levels of domestic cats undergoing right hepatic lobectomy

OBJECTIVE: This controlled study was done to determine the protective effects of ischemic preconditioning (IP) on the liver of cats undergoing major liver resection.SPECIFIC OBJECTIVE: To determine the effect of IP on alanine transaminase (ALT or SGPT) in cat*that will undergo major liver resection.DESIGN: This study is a randomized controlled trial.SETTING: LIST Health Sciences Research Laboratory.PATIENTS/ PARTICIPANTS: This is an experimental study on the effects of ischemic preconditioning under hepatic inflow occlusion on the SGPT as a measure of morbidity in Felis catus (domestic cats) undergoing right hepatic lobectomy. Nine male cats, weighing 2.5-5kg, are equally allocated into any one of the following 3 study groups: Control group not subjected to ischemic preconditioning (C), Experimental group subjected to 1 1/2 minutes of ischemia followed by 1.5 minutes of reperfusion (El), Experimental group subjected to 5 minutes of ischemia followed by 5 minutes of reperfusion (E2).RESULTS: There was no significant difference in the mean weight of cats in the 3 groups (p = 1.00). Comparing the pre and post result between using paired t-test, there was no significant difference in the baseline values (p = 0.14). However, there was a significant difference in the post result between the three groups (p CONCLUSION: In the past few years, interesting new data on the presence of ischemic preconditioning in various organs as an endogenous means to protect itself from ischemiahas been available. This study investigated and suggests that ischemic preconditioning may provide protection to the liver undergoing hepatic lobectomy.

A multicenter randomized clinical trial comparing the clinical efficacy of Imipenem/Cilastin and Ceftazidime plus Metronidazole in surgically treated serious intra-abdominal infections

An open, prostective, randomized multicenter clinical trial randomly allocated successive patient who were scheduled for a surgical procedure for serious intra-abdominal infections to receive either treatment CM (ceftazidine plus metronidazole) or monotherapy with treatment IC (imipenem/cilastatin). Out of 90 eligible patients, 87 were clinically evaluable of which 71 were clinically and bacteriologically evaluable (CBE). Cases allocated to each treatment group were comparable as to age, sex, diagnostic group distribution, mean APACHE II scores, and bacteriologic evaluability. Among the 87 clinically evaluable patients, there were 4 (9.1%) and 2 (4.7%) treatment failures among those who received treatments CM and IC respectively (p=0.486). For all eligible patients, the mean fever days was 2.07, mean treatment days was 6.01, and mean hospital days was 11.57, and was not significantly different between the two treatment groups. Among clinically evaluable cases, the mean APACHE II scores of patients with succesful outcomes (5.8) was very significantly lower (p=0.000) than that of patients whose treatment failed (13.8). This was also true for CBE cases. Logistic regression analysis showed that among six variables (diagnostic group, APACHE II score, antibiotic used, fever days, hospital days and treatment days) only the APACHE II score signficantly contributed to treatment failure (p=0.001).